

NOVA University of Newcastle Research Online

nova.newcastle.edu.au

Brosseau, Lucie; Toupin-April, Karin; Cavallo, Sabrina et. al. 'Ottawa panel evidencebased clinical practice guidelines for foot care in the management of juvenile idiopathic arthritis'. Published in Archives of Physical Medicine and Rehabilitation Vol. 97, Issue 7, p. 1163-1181 (2016)

Available from: http://dx.doi.org/10.1016/j.apmr.2015.11.011

© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <u>http://creativecommons.org/licenses/by-nc-nd/4.0/</u>

Accessed from: http://hdl.handle.net/1959.13/1321358

1	Ottawa Panel Evidence-Based Clinical Practice Guidelines for Foot Care in the Management of
2	Juvenile Idiopathic Arthritis
3	Abstract:
4	Objective: To create evidence-based guidelines evaluating foot care interventions for the management of
5	juvenile idiopathic arthritis (JIA).
6	Data Sources: An electronic literature search of the following databases from database inception until
7	May 2015 was conducted: Medline (Ovid), Embase (Ovid), Cochrane CENTRAL, and clinicaltrials.gov.
8	Study Selection: The Ottawa Panel selection criteria targeted studies that assessed foot care or foot
9	orthotic interventions for JIA management among those ages 0 to \leq 18 years old. The Physiotherapy
10	Evidence Database (PEDro) scale was used to evaluate study quality, of which only high quality studies
11	were included (score ≥ 5). A total of 362 records were screened, resulting in three full text articles and
12	one additional citation containing supplementary information included for analysis.
13	Data Extraction: Two reviewers independently extracted study data (intervention, comparator, outcome,
14	time period, and study design) from included studies, using standardized data extraction forms. Directed
15	by Cochrane collaboration methods, the statistical analysis produced figures and graphs representing the
16	strength of intervention outcomes and their corresponding grades (A, B, C+, C, C-, D+, D, D-). Clinical
17	significance was achieved when an improvement of 30% or more between intervention and control
18	groups was present, whereas p > 0.05 indicated statistical significance. An expert panel Delphi
19	consensus (\geq 80%) was required for recommendation endorsement.
20	Data Synthesis: All included studies were of high quality and analyzed the effects of multidisciplinary foot
21	care, customised foot orthotics, and shoe inserts for the management of JIA. Custom-made foot orthotics
22	and pre-fabricated shoe inserts displayed the greatest improvements in pain intensity, activity limitation,
23	foot pain, and disability reductions (grades A, C+).
24	Conclusions: The use of customised foot orthotics and pre-fabricated shoe inserts seems to be a good
25	choice for managing foot pain and function in JIA.
26	Key words: Foot orthotics, Juvenile Idiopathic Arthritis, Physiotherapy, Podiatry, Pediatric rheumatology
27	

28 Abbreviations: JIA Content

AGREE	Appraisal of Guidelines for Research and Evaluation
CCT	Clinical Control Trial
EBCPG	Evidence-Based Clinical Practice Guidelines
JIA	Juvenile Idiopathic Arthritis
MCID	Minimal Clinical Important Difference
OMERACT	Outcome Measures for Rheumatoid Arthritis Clinical Trials
OMG	Ottawa Methods Group
PEDro	Physiotherapy Evidence Database
PRISMA	Preferred Reporting Items for Systematic and Meta-Analyses
RCT	Randomised Control Trial

29

30 Abbreviations: Intervention Outcomes/Instruments

CHAQ	Childhood Health and Assessment Questionnaire
EQ-5D VAS	EuroQol – 5 Dimensions Visual Analogue Scale
FFI	Foot Function Index
JAFlimp	Juvenile Arthritis Foot Disability Index – Impairment
JAFIal	Juvenile Arthritis Foot Disability Index – Activity Limitation
JAFIpr	Juvenile Arthritis Foot Disability Index – Participation Restriction
PedsQL	Pediatric Quality of Life Inventory
VAS	Visual analogue scale

31

32 Target Population

33 Patients with juvenile idiopathic arthritis (JIA) accompanied by family members (e.g. parents/guardians)

34 as well as different types of health professionals such as registered nurses, podiatrists, pediatricians,

35 rheumatologists, and exercise physiologists, can refer to this evidence-based clinical practice guideline

- 36 (EBCPG). Arthritis based institutions and charity groups (e.g. The Arthritis Society, etc.) may also find this
- 37 EBCPG to be of interest. This guideline primarily targets those between the ages of 3 and 19 years old
- 38 with varying disease durations (1 month to 18 years).

39

40 Introduction

41 Juvenile idiopathic arthritis (JIA), is a prevalent chronic childhood autoimmune disease¹ that can cause 42 disability in areas of the body with higher weight-bearing demands such as the foot. Foot problems (e.g. 43 inflammation, limitation of motion) often arise among JIA patients due to affected joints, which 44 consequently impact the feet and lead to pain, deformities², and malalignment³. Foot care and foot orthotics are often used by patients with rheumatoid arthritis⁴⁻⁸, and have been shown to relieve pain by 45 46 adjusting biomechanical deformities and lower limb misalignments⁹. Although deformities and foot pain 47 are common to arthritis, foot care is infrequently considered as part of an overall management approach for JIA and represents a neglected area of study¹⁰. 48

49

55

50 The management of JIA is frequently viewed through a multi-disciplinary lens, incorporating

51 pharmacological and psychological interventions, along with physical and occupational therapy¹¹.

Unfortunately, published EBCPGs and systematic reviews investigating the use of non-pharmacological
 interventions, like foot care, for managing JIA lack substantial evidence and are outdated¹²⁻¹⁵. There is a

54 strong need to update EBCPGs based on a quantitative and systematic methodology in order to develop

rigorous recommendations on effective foot care management solutions for JIA. The proposed Ottawa

56 Panel evidence based clinical practice guideline (EBCPG) is based on a systematic review and has

57 consolidated all non-pharmacological foot care management options for JIA. The primary objective of this

58 Ottawa Panel EBCPG was to develop evidence-based recommendations on foot care interventions for

59 JIA based on a critical appraisal of comparative controlled studies. The secondary objective was to

60 determine the strength of existing evidence-based research on foot care interventions for JIA. The third

and final objective was to identify the most effective foot care interventions for JIA. In order to promote
foot care for JIA management, stakeholders will require access to recent, high quality recommendations

- 63 as presented within this EBCPG.
- 64

65 Methods

66 Development process of the Ottawa Panel EBCPG

The development of this Ottawa Panel EBCPG was informed by previous Ottawa Panel EBCPGs¹⁶⁻¹⁹ and
its methodology follows the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA)
checklist²⁰. The major components of the Ottawa Panel EBCPG include: 1) a systematic search of the
literature as per Cochrane Collaboration methodology²¹; 2) inclusion of articles according to selection
criteria, 3) study quality assessment, 4) data extraction and synthesis, 5) quantitative grading system²²;
health expert review and endorsement of recommendations, and 7) planned dissemination of results.

74 The Ottawa Panel

75 The Ottawa Panel consists of the Ottawa Methods Group (OMG), which develops the EBCPG, and the 76 Expert Panel, which reviews and approves EBCPG recommendations through a consensus process. The OMG produced evidence tables containing study data and developed recommendations for the draft 77 78 EBCPG. The expert panel, which includes 15 experts: 1 physician, 6 physiotherapists, 1 occupational therapist, 2 exercise physiologists, 3 chiropodists/podiatrists and 2 consumer experts (parent and child), 79 80 were sent draft EBCPG recommendations for independent review. The patient and parent consumer experts also reviewed draft EBCPG content and recommendations that had been translated into lay 81 82 terms.

83

84 Endorsing the recommendations

An online Delphi questionnaire served as an EBCPG evaluation tool for members of the Expert Panel. Experts provided feedback on EBCPG layout, level of detail, clarity and relevance (part one), as well as whether they endorsed guideline recommendations for study interventions (part two). A structured Delphi questionnaire was used, contrary to an open question format, seeing as a quantitative grading scale determined guideline recommendations rather than clinical impressions²³. Within the two parts of the Delphi questionnaire, experts were asked to evaluate the guideline using a 5-point Likert scale (1 being "not clear" or "strongly disagree" and 5 being "very clear" or "strongly agree") and respond to yes or no

92 questions investigating the clarity, agreement, and understanding of each recommendation. Upon receipt 93 of all expert panel surveys, the level of group consensus was determined using statistical calculations 94 performed in Excel (measures of central tendency and frequency). If consensus was not met, a second 95 round was required where a revised manuscript with highlighted corrections was circulated along with a 96 coded Excel spread sheet displaying experts' responses. These rounds continued until a consensus of at 97 least 80% is reached or until the law of diminishing returns was observed²⁴ for questions within part 1 and 98 part 2 of the survey.

99

100 Selection Criteria

101 The selection criteria for this EBCPG was determined a priori by the Ottawa Methods Group and followed the population, intervention, comparators, outcomes, period of time, and study design (PICOTS) strategy. 102 103 A list of the selection criteria is presented in Appendix 1. The search strategy was conducted from 104 database inception to May 2015 and performed in Medline (Ovid), Embase (Ovid), Cochrane CENTRAL 105 (Ovid) and clinicaltrials.gov. Two reviewers (CS and JT) independently screened article titles and abstracts to determine if they met the inclusion criteria. Articles featuring foot care management 106 107 interventions for JIA were selected for this EBCPG from a larger systematic literature search and network meta-analysis review conducted by Smith (in progress)²⁵. The PRISMA diagram is shown in Appendix 2. 108 109

110 Methodological Quality of Included Studies

Each included study was evaluated using the PEDro scale, an appropriate tool for assessing the methodological quality of non-pharmacological studies^{26 27}. This 10-point scale has been shown to be a valid and reliable assessment tool²⁸⁻³², and is frequently used to assess randomized control trials (RCTs) validity and interpretability. This EBCPG will use a 5 out of 10 cut-off score in order to only include moderate to high quality articles in the analysis³³.

116

117 Outcomes

Outcome measure data from included studies were analysed if outcome measures were validated and reliable or met the Outcome Measures for Rheumatoid Arthritis Clinical Trials (OMERACT)^{34,35} criteria. Included studies must have measured a minimum of one of the inclusion criteria outcomes and used validated measures during outcome assessment. All end of treatment and follow-up (retention effect) outcome measures were presented in months in order to maintain consistency throughout the EBCPG.

124 Statistical Analysis

Reference Manager (version 5.3)³⁶, meta-analysis software, was used to analyse EBCPG data. The mean difference was calculated at end of treatment and follow-up for continuous outcome measurement data (the mean, standard deviation, and sample size). The mean difference is used to measure "the absolute difference between the mean values in two groups"²¹, which can help determine if an intervention has had a significant effect on the intervention group compared to the control. Articles that were missing relevant data required for statistical analysis and whose authors were unable to be contacted were excluded.

132

133 Additionally, EBCPG figures and graphs were created using study data and statistics, as per Cochrane Collaboration methodology^{37,38}. For each figure the mean difference between groups is represented by a 134 135 square and the SD is represented by a horizontal line. No statistically significant difference between intervention and control groups is present if the horizontal line crosses the graph's center vertical line. 136 137 This EBCPG defines the relative difference between the intervention and control group of \geq 30% to be a clinically important improvement (minimal clinically important difference: MCID), which is supported by the 138 139 American College of Rheumatology (ACR) Pediatric 30 response criteria (JIA disease activity 140 measure)^{39,40}. Calculations on the absolute benefit and the relative difference in change from baseline 141 were used to determine clinical importance⁴¹.

- 143 The level of evidence (e.g. level I for RCTs and level II for CCTs), clinical importance based on the MCID
- 144 (MCID \ge 30%), and statistical significance (p < 0.05) were used to determine recommendation grades.
- 145 For a description of each grade see Table 1.
- 146
- 147
- 148 Results
- 149 Literature search

A total of 535 records along with one supplementary citation (provided by author⁴²) were retrieved upon 150 151 completion of the systematic search. Once duplicates were removed, 362 records were screened. According to the selection criteria, three full-text articles⁴³⁻⁴⁵ and one supplementary citation⁴² met the 152 inclusion criteria and were included for final analysis. The additional citation was a book that provided 153 154 supplementary raw RCT data that corresponded to one of the included studies⁴⁴. Included studies did not 155 share the same PICOTS therefore heterogeneity (chi-square statistic or l²) was not calculated. Where published data was non-parametric and median and interquartile range (IQR) was calculated, raw data 156 were required from authors^{44,45}. Raw data was used to calculate mean and SD to determine graded 157 158 recommendations (Cochrane Collaboration methodology). 159 Out of the 362 records, 321 articles were excluded because they were related to pharmacological interventions only. Therefore, 40 full-text articles were assessed for eligibility. As mentioned above, only 3 160 articles and 1 citation met the inclusion criteria, and 29 full-text articles were excluded. The 29 trials did 161 162 not meet the inclusion criteria for the following reasons: (1) inadequate patient population⁴⁶ (2) no mention of foot orthotics⁴⁷⁻⁶⁰ (3) inadequate study design⁶¹⁻⁶³ (4) insufficient data available⁶⁴⁻⁶⁹ (5) inappropriate 163 outcomes^{70,71} (6) not considered as a full-text⁷²⁻⁷⁴. 164

165

166 Study Characteristics

167 This EBCPG includes studies that analysed the effectiveness of foot care interventions to reduce pain,

168 and improve function and quality of life in children with JIA. The three included RCTs included JIA

169 patients between the ages of 3 and 19 years old⁴³⁻⁴⁵. One study randomized participants to receive either "fitted" Foot Orthoses (FO) or 1 mm uncorrected leather boards (control)⁴⁴ and another study compared 170 171 three interventions: custom-fabricated semi-rigid orthotics, pre-fabricated shoe-inserts, and new athletic 172 shoes with soles⁴³. The third study allocated participants to either a multidisciplinary foot care group or a 173 usual care group (control)⁴⁵. Pain relief (VAS Scale)⁴⁴, activity limitation (Foot Function Index (FEI) 174 scales)⁴³ and foot-related disability (Juvenile Arthritis Foot Disability Index (JAFI))⁴⁵ were the primary outcomes of these three RCT studies, respectively. For additional information on study characteristics 175 176 and population demographics refer to Appendix 3.

177

178 Delphi results

Among the 15 experts who were invited to complete the first round of the Delphi questionnaire, 100% 179 180 provided answers (15/15). All part one questions (except Q.4) failed to achieve consensus. In part two, 181 nine (out of 15) questions had strong consensus (≥ 80%), whereas six questions (7A, 10J, 10K, 10L, 11M, 11O) obtained moderate consensus (between 67% and 73%). The second Delphi round achieved 182 strong (Q. 2 & 3) and moderate (Q. 1 & 4), and poor (Q. 5 & 6) consensus for part one, and full 183 184 consensus for all questions in part two. Since the majority of the survey achieved consensus, a third round was not prepared. Rather, expert suggestions were addressed accordingly and on a case by case 185 186 basis.

187

188 Excluded outcome measures

Body mass index (BMI) has been shown to have a low level of validity and was subsequently excluded from the analysis⁷⁵. Active and limited joint count (0-77) are commonly regarded as biomedical outcome measures³⁹ (not specific to feet), and thus have also been excluded from our analysis.

192

193 Results of the included studies

194 Methodological quality (PEDro scores of included studies)

- All included RCTs were assessed to be of high quality, with a PEDro score of 6 to 7 out of 10⁴³⁻⁴⁵. A
- summary of recommendations and their corresponding PEDro scores are provided in Appendix 4.
- 197
- 198 Effectiveness of foot care for foot pain and functional management of JIA
- 199 The findings from included RCTs exploring the effectiveness of foot care and orthotics for foot pain and
- 200 functional management of JIA will be briefly outlined below. Additional information on these studies (mean
- 201 difference, sample size, etc.) can be found in Appendix 3. RCTs investigated the effectiveness of fitted or
- 202 custom made foot orthoses^{43,44} as well as multidisciplinary foot care⁴⁵ for JIA outcomes.
- 203
- 204 Fitted foot orthoses vs Control foot orthoses (leather board; 1 mm)⁴⁴
- 205 One level 1 RCT examined the effects of custom-fitted foot orthoses (n = 31) versus control foot orthoses
- 206 $(n = 29)^{44}$ (Appendix 5). Participants were randomised into the intervention group (custom-fitted foot
- 207 orthoses) or control group (Appendix 3).
- At 3 months (end of intervention), the Ottawa Panel found no clinical benefit (grade C) supporting fitted foot orthoses for pain reduction (100-mm VAS) (Figure 1), quality of life (Paediatric rheumatology PedsQL), quality of life (Parent rheumatology PedsQL), quality of life (Child generic), quality of life (Parent generic), CHAQ, and gait velocity (cm/sec). Neutral evidence (with no clinical benefit) favouring the control (grade D) was demonstrated for gait time (sec). Additional figures (Figures S7-S13) are available in supplemental files.
- At 6 months (end of intervention), the Ottawa Panel found clinically important benefits without statistical significance (grade C+) for fitted foot orthoses in pain reduction (100-mm VAS). No clinical benefit (grade C) was observed for quality of life (Paediatric rheumatology PedsQL), quality of life (Parent rheumatology PedsQL), quality of life (Child generic), quality of life (Parent generic), CHAQ, gait time (sec), and gait velocity (cm/sec). Additional figures (Figures S14-S21) and Table (Table S3) are available in supplemental files.

220

This study received a PEDro score rating of 7 out of 10 (high methodological quality). The Ottawa Panel 221 suggests the use of custom fitted preformed foot orthotics (versus 1 mm non-customised leather 222 **board control)** for at least 6 months, in order to decrease pain (100-mm VAS) following \geq 24 weeks⁴⁴.

223

Custom-made semi-rigid orthotics vs pre-fabricated off-the-shelf shoe inserts⁴³ 224

225 One level 1 RCT made 3 comparisons⁴³. First, the effects of custom-made semi-rigid orthotics (n = 15) 226 versus a pre-fabricated off-the-shelf shoe insert (n = 12) were explored (Appendix 3). The custom-made 227 semi-rigid orthotics were made of metal particle-reinforced polyolefin with shock absorbing functional 228 posts.

At 3 months (end of intervention), the Ottawa Panel suggests the use of custom-made semi-rigid 229 230 orthotics which showed clinically important benefits without statistical significance (grade C+) for pain 231 intensity (Pediatric Pain Questionnaire VAS), activity limitation (FFI), foot pain (FFI) (Figure 2) and disability. No clinical benefit (grade C) and thus no clinically important benefit was observed for timed 232 walking (sec), physical functioning (PedsQL 4.0, child self-report), and physical functioning (PedsQL 4.0, 233 234 parent proxy-report). Additional figures (Figures S30-S35) and Table (Table S4) are available in 235 supplemental files

236 This study received a PEDro score rating of 7 out of 10 (high quality methodology). The Ottawa Panel 237 suggests the use of custom-made semi-rigid orthotics (versus pre-fabricated off-the-shelf shoe 238 inserts) for at least 3 months, in order to decrease pain (intensity; PPQ-VAS), activity limitation (FFI), foot 239 pain (FFI), and reduce disability (FFI) following \geq 12 weeks⁴³.

240

241 Custom-made semi-rigid orthotics vs new supportive athletic shoes⁴³

- In this same RCT, the effects of custom-made semi-rigid orthotics (n = 15) versus new supportive athletic shoes were explored (n = 13) (Appendix 3).
- At 3 months (end of intervention), the Ottawa Panel found stronger evidence for custom-made semi-
- rigid orthotics which exhibited clinically important benefits with statistical significance (grade A) for pain
- intensity (Pediatric Pain Questionnaire VAS), activity limitation (FFI) (Figure 3), foot pain (FFI) and
- 247 disability (FFI) (Figure 4). No clinical benefit (grade C) was observed for timed walking (sec), physical
- functioning (PedsQL 4.0, child self-report), and physical functioning (PedsQL 4.0, parent proxy-report).
- Additional figures (Figures S36-S40) and Table (Table S5) are available in supplemental files.

This study received a PEDro score rating of 7 out of 10 (high quality methodology). The Ottawa Panel suggests the use of **custom-made semi-rigid orthotics (versus new supportive athletic shoes)** for at least 3 months, in order to decrease pain (intensity; PPQ-VAS), activity limitation (FFI), foot pain (FFI), and reduce disability (FFI) following \geq 12 weeks⁴³.

254

255 Pre-fabricated off-the-shelf shoe inserts vs new supportive athletic shoes⁴³

Again, in the same study, the effects of pre-fabricated off-the-shelf shoe inserts (n = 13) versus new

supportive athletic shoes were explored (n = 12) (Appendix 3).

At 3 months (end of intervention), the Ottawa Panel suggests the use of pre-fabricated off-the-shelf

shoe inserts which showed clinically important benefits without statistical significance (grade C+) for pain

260 intensity (observed; Pediatric Pain Questionnaire VAS). No clinical benefit (grade C) was found for timed

walking (sec) (Figure 5), activity limitation (FFI), foot pain (FFI), disability (FFI), physical functioning

- 262 (PedsQL 4.0, child self-report) and physical functioning (PedsQL 4.0, parent proxy-report). Additional
- figures (Figures S41-S46) and Table (Table S6) are available in supplemental files.

265	This study received a PEDro score rating of 7 out of 10 (high methodological quality). The Ottawa Panel
266	suggests the use of pre-fabricated off-the-shelf shoe inserts (versus new supportive athletic shoes)
267	for at least 3 months, in order to reduce pain (intensity; PPQ-VA) following \geq 12 weeks ⁴³ .
268	
269	Multidisciplinary foot care vs standard foot care ⁴⁵
270	One level 1 RCT explored the combined effects of multidisciplinary foot care ($n = 21$) versus standard foot
271	care $(n = 23)^{45}$ (Appendix 3).
272	At 6 months (end of intervention), the Ottawa Panel found no clinical benefit (grade C) for
273	multidisciplinary foot care for impairment (JAFlimp) and participation restriction (JAFIpr). Neutral evidence
274	(with no clinical benefit) was also found favouring the control (grade D) for activity limitation (JAFIal).
275	Additional figures (Figures S22-S24) and Table (Table S7) are available in supplemental files.
276	At 12 months (end of treatment), the Ottawa Panel found no clinical benefit (grade C) demonstrated for
277	multidisciplinary foot care for activity limitation (JAFIal), participation restriction (JAFIpr) (Figure 6), pain
278	(VAS), and health related quality of life (EQ-5D VAS self). Neutral evidence (with no clinical benefit) was
279	found favouring the control (grade D) for impairment (JAFlimp), global functional status (CHAQ), and
280	health related quality of life (EQ-5D VAS proxy), however clinically important benefit was not
281	demonstrated. Additional figures (Figures S25-S29) and Table (Table S8) are available in supplemental
282	files.
_	
283	This study received a PEDro score rating of 6 out of 10 (high methodological quality). There was no
284	clinical benefit demonstrated for any assessed outcomes therefore the Ottawa Panel cannot reasonably
285	recommend multidisciplinary foot care (versus standard foot care) for the management of JIA.
286	

287 Discussion

288 This Ottawa Panel EBCPG developed recommendations on three high quality studies (PEDro score \geq 5) 289 evaluating foot care interventions for foot pain and functional management of JIA⁴³⁻⁴⁵. Foot orthoses 290 (custom fitted preformed FOs, custom made FOs) received positive recommendations since they achieved clinical importance with statistical significance (Grade A: pain⁴³, activity limitations⁴³, disability⁴³). 291 292 Positive recommendations were also shown for outcomes that obtained clinical significance without 293 statistical significance (Grade C+: pain^{43,44}, activity limitation⁴³, disability⁴³). A total of 10 positive 294 recommendations were represented among the 3 included studies. Overall, evidence suggests that foot 295 care interventions (foot orthotics) can improve foot pain (intensity) (2 grade A and 4 grade C+), activity 296 limitation (1 grade A and 1 grade C+), and disability (1 grade A and 1 grade C+) in children with JIA. The 297 remaining recommendations are listed as follows: 31 outcomes graded as C and 6 outcomes graded as 298 D.

299

The Ottawa Panel methodology used in this EBCPG has been shown to be clear and rigorous, as determined through an Appraisal of Guidelines Research and Evaluation (AGREE) II assessment⁷⁶. Previous EBCPGs that followed Ottawa Panel methodology effectively addressed 4 out of 6 domains on the AGREE II Instrument (scope and purpose, stakeholder involvement, rigour of development, and clarity of presentation), and were thus deemed to be high quality guidelines (> 60%)⁷⁷.

305

306 Studies that have evaluated foot care interventions have frequently recommended its use for OA (hip and 307 knee) pain management. For example, both the American College of Rheumatology (ACR)⁷⁸ and the European League Against Rheumatism (EULAR)⁷⁹ recommended foot insoles (medial, lateral, or subtalar 308 309 strapped lateral wedge) as a beneficial management tool for knee OA among adults^{80,81}. Although systematic reviews have stated that (custom-made) shoe insoles for alternative pediatric foot problems 310 311 (e.g. excess pronation of feet, flat feet, etc.) have minimal to no beneficial effect^{13,82}, some have shown improvement in foot pain in patients with musculoskeletal conditions, including JIA¹⁵. It is unclear if this is 312 313 a general trend, seeing as there are currently no published systematic reviews investigating the effect of

foot orthotics specifically on JIA patients. In light of this, it is evident that more RCTs evaluating the
effects of foot care interventions for people with JIA, especially with a larger sample size, are required.

317 For many suffering from JIA and other forms of arthritis (e.g. hip and knee), the foot can be a major source of pain and impaired physical functioning⁸³. Modifiable footwear, such as foot orthotics and 318 319 insoles, have be shown to reduce lower extremity stress through the realignment and adjustment of gait pattern and foot muscle activation^{84,85}. This leads to a reduction of biomechanical stress loading on the 320 321 joint and increases favourable muscle activity which may provide therapeutic relief for those affected by 322 RA, OA, or JIA^{86,87}. Currently, few studies have confirmed a strong association between arthritis 323 development and foot form and function, particularly among the JIA population. 324 Although foot orthoses have been shown to be effective, the literature has indicated poor patient 325 compliance among those wearing orthotic devices for therapeutic benefit. One systematic review 326 investigating the compliance of (OA, RA, etc.) patients with orthotic devises for the lower extremities 327 confirmed a high percentage of patients choosing to not use prescribed orthotic devices, due to varying 328 reasons including pain and discomfort⁸⁸. One study had a low attrition rate⁴³, whereas another study 329 displayed difficulties achieving an appropriate number of patients⁴⁵. The third study was overpowered in anticipation of potential dropouts⁴⁴. Interestingly, those who left the study (if required) declared reasons 330 other than pain or discomfort as their primary motivation⁴³⁻⁴⁵. Although most included studies evaluated 331 332 the effect of foot care interventions in the short term, one study noted that compliance was associated with comfort43. 333

334

335 Limitations

336 Limitations of the Ottawa Panel EBCPG

Clinical discretion is advised upon reading EBCPG foot care recommendations due to wide confidence
 intervals and the limited number of included RCTs analysed in this guideline. Therefore, it is possible for
 primary RCTs⁴³⁻⁴⁵ to have found significant findings within their study that may not be statistically
 significant within this EBCPG and may not have received a positive recommendation (e.g. grade C+). In

341 addition, non-parametric raw data was requested from authors in order to calculate the mean and SD 342 (parametric statistics required for determining recommendations). This unavoidable conflict may have produced skewed results for some outcomes measures, potentially rendering significant outcomes (in 343 344 primary studies) as insignificant within the EBCPG. As a result, the Ottawa Panel recommendations are 345 conservative. In addition, it is possible to consider various MCIDs according to the outcome assessed 346 within included RCTs. For instance, the MCID for the visual analogue scale (VAS) for pediatric rheumatology is 8 mm⁹⁰, while the Pediatric Quality of Life Inventory (PedsQL) is 5 mm⁹¹. To overcome 347 this problem a standard MCID score of 30% for each outcome was used to determine if a clinically 348 important benefit was detected^{39,40}. It is possible, however, for outcome clinical improvement (at end of 349 350 treatment and follow up) to remain undetected while applying a standardised MCID of 30%.

351

352 Limitations of the primary included studies

One RCT⁴⁵ conducted an ANOVA statistical analysis to analyse raw data, therefore in order to determine 353 which intervention was statistically significant, interventions were analysed in pairs (mean and relative 354 difference). Additionally, the study⁴⁵ intervention group received more intra-articular cortico-steroid 355 356 injections (ICIs) than the control group (13 ICIs vs 7 ICIs) although it is unclear if this difference is 357 statistically significant or if the quantity of ICIs administered had a biased influence on this group. It is 358 important to note that inconsistencies were present between our EBCPG recommendations and the conclusions from included RCTs for the following outcomes: pain relief (VAS)⁴⁴, quality of life (PedsQL – 359 paediatric rheumatology)⁴⁴, guality of life (parent rheumatology)⁴⁴, guality of life (PedsQL – child 360 generic)⁴⁴, and quality of life (PedsQL – parent generic)⁴⁴. Thus, the Ottawa Panel recommendations 361 362 remain conservative (i.e. grade C+) regardless of statistically significant results for certain outcomes in 363 the primary RCTs.

364

Appendices 6,7,8 provides additional details on conflicting outcome measures and corresponding gradings which may assist clinicians in interpreting these results. Self-reported outcome measures, such as pain and quality of life, may introduce information bias which should be taken into consideration when

368 applying these recommendations in practice. Furthermore, parent proxy-reports (e.g. physical function),

369 where parents may be subjectively influenced, can present the same issue. Although all included studies

370 were considered high quality³¹, their small sample size should also be considered when interpreting

- 371 findings.
- 372

373 Conclusion

374 The Ottawa Panel found moderate evidence to support the use of foot care in foot pain and functional

375 management of patients with JIA between the ages of 3 and 19 years with varying disease durations.

- According to three high quality RCTs, foot orthotics (preformed, custom fitted or custom made) can
- 377 produce beneficial effects among patients with JIA, particularly for reducing foot pain and activity
- 378 limitation. It would be interesting to explore the impact of JIA disease duration on the effect of foot care for

foot pain and functional management in JIA and how foot care management options can be improved to

increase therapeutic effect. Given the lack of research in this field, more RCTs with larger sample sizes

381 are warranted to more accurately determine the effect of foot care on JIA patients and to confirm any

382 beneficial long term effects.

385 References

- 386 1. Cassidy JT, Petty RE. Chronic arthritis in childhood. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB,
- 387 eds. *Textbook of pediatric rheumatology*. Philadelphia, USA: Elsevier Saunders; 2005:206-60.
- 388 2. Merker J, Hartmann M, Kreuzpointner F, Schwirtz A, Haas JP. Pathophysiology of juvenile idiopathic
- 389 arthritis induced pes planovalgus in static and walking condition-A functional view using 3d gait analysis.
- 390 *Pediatr Rheumatol Online J.* 2015;13:21-015-0022-z.
- 391 3. Spraul G, Koenning G. A descriptive study of foot problems in children with juvenile rheumatoid arthritis
 392 (JRA). *Arthritis Care Res.* 1994;7(3):144-50.
- 4. Mejjad O, Vittecog O, Pouplin S, Grassin-Delyle L, Weber J, Le Loët X. Foot orthotics decrease pain
- but do not improve gait in rheumatoid arthritis patients. *Joint Bone Spine*. 2004;71(6):542-545.
- 395 5. Conrad KJ, Budiman-Mak E, Roach KE, et al. Impacts of foot orthoses on pain and disability in
- 396 rheumatoid arthritics. J Clin Epidemiol. 1996;49(1):1-7.
- 397 6. Hodge MC, Bach TM, Carter GM. Novel award first prize paper. orthotic management of plantar
- 398 pressure and pain in rheumatoid arthritis. *Clin Biomech (Bristol, Avon)*. 1999;14(8):567-575.
- 399 7. Woodburn J, Helliwell PS, FAU Barker S, Barker S. Changes in 3D joint kinematics support the
- 400 continuous use of orthoses in the management of painful rearfoot deformity in rheumatoid arthritis. J
- 401 *Rheumatol.* 2003;30(11):2356-64.
- 402 8. Pallari JH, Dalgarno KW, Woodburn J. Mass customization of foot orthoses for rheumatoid arthritis
 403 using selective laser sintering. *IEEE Trans Biomed Eng.* 2010;57(7):1750-1756.
- 9. Donatelli RA, Hurlburt C, et al. Biomechanical foot orthotics: A retrospective study. *J Orthop Sports Phys Ther.* 1988;10(6):205-12.

406 10. Ollier W, Worthington J. Small fish in a big pond. *Rheumatology*. 1997;36(9):931-932.

- 407 11. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. *JAMA*. 2005;294(13):1671408 1684.
- 409 12. Dueckers G, Guellac N, Arbogast M, et al. Evidence and consensus based GKJR guidelines for the
- 410 treatment of juvenile idiopathic arthritis. *Clin Immunol.* 2012;142(2):176-193.
- 411 13. Whitford D, Esterman A. A randomized controlled trial of two types of in-shoe orthoses in children with
- 412 flexible excess pronation of the feet. Foot Ankle Int.2007;28(6):715-23.
- 413 14. Munro J, Brun S, Rawlin M, Webster P, Grimmer-Somers K, Jasper A, Rada J, Haesler E, Allen R,
- 414 Akikusa JD, Boros C, Piper S, Adib N, Murray KJ, Chaitow J. Clinical guideline for the diagnosis and
- 415 management of juvenile idiopathic arthritis. vol. 5-6. pp. 20-21. South Melbourne, Victoria; 2009:20-21.
- 416 15. Hawke F, Burns J, Radford JA, du Toit V. Custom-made foot orthoses for the treatment of foot pain. -
- 417 Cochrane Database Syst Rev.2008 Jul 16;(3):CD006801.doi: 10.1002/14651858.CD006801.pub2.
- 418 16. Brosseau L, Wells GA, Poitras S, et al. Ottawa panel evidence-based clinical practice guidelines on
- therapeutic massage for low back pain. J Bodyw Mov Ther. 2012;16(4):424-455.
- 420 17. Brosseau L, Wells GA, Tugwell P, et al. Ottawa panel evidence-based clinical practice guidelines on
 421 therapeutic massage for neck pain. *J Bodyw Mov Ther*. 2012;16(3):300-325.
- 18. Brosseau L, Wells G, Tugwell P, et al. Ottawa panel evidence-based clinical practice guidelines for
 electrotherapy and thermotherapy interventions in the management of rheumatoid arthritis in adults. *Phys Ther.* 2004;84(11):1016-1043.

- 425 19. Cavallo S, Brosseau L, Toupin-April K, et al. Ottawa panel evidence-based clinical practice guidelines
- 426 for physical activity in the management of juvenile idiopathic arthritis. Archives of Physical Medicine and
- 427 *Rehabilitation*. Manuscript submitted for publication.
- 428 20. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Reprint--preferred reporting items for
- 429 systematic reviews and meta-analyses: The PRISMA statement. *Phys Ther.* 2009;89(9):873-880.
- 430 21. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. 5.1.0 ed. The
- 431 Cochrane Collaboration; 2011.
- 432 22. Brosseau L, Wells GA, Tugwell P, et al. Ottawa panel evidence-based clinical practice guidelines for
- 433 the management of osteoarthritis in adults who are obese or overweight. *Physical Therapy*.
- 434 2011;91(6):843-861.
- 435 23. Hsu C, Sandford BA. The delphi technique: Making sense of consensus. Practical Assessment,
- 436 Research & Evaluation. 2007;12(10).
- 437 24. Hasson F, Keeney S, McKenna H. Research guidelines for the delphi survey technique. *J Adv Nurs*.
 438 2000;32(4):1008-1015.
- 439 25. Smith CAM. Pharmacological and non-pharmacological interventions in juvenile idiopathic arthritis: A
 440 series of systematic reviews and network meta-analyses protocol. Ottawa: University of Ottawa; In
 441 progress.
- 26. Armijo-Olivo S, Ospina M, da Costa BR, et al. Poor reliability between cochrane reviewers and
 blinded external reviewers when applying the cochrane risk of bias tool in physical therapy trials. *PLoS One.* 2014;9(5):e96920.
- 445 27. de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: A
 446 demographic study. *Aust J Physiother*. 2009;55(2):129-33.

28. Elkins MR, Moseley AM, Sherrington C, Herbert RD, Maher CG. Growth in the physiotherapy

evidence database (PEDro) and use of the PEDro scale. *Br J Sports Med.* 2013;47(4):188-189.

449 29. Bhogal SK, Teasell RW, Foley NC, Speechley MR. The PEDro scale provides a more comprehensive

450 measure of methodological quality than the jadad scale in stroke rehabilitation literature. J Clin Epidemiol.

451 2005;58(7):668-673.

452 30. Foley NC, Bhogal SK, Teasell RW, Bureau Y, Speechley MR. Estimates of quality and reliability with

453 the physiotherapy evidence-based database scale to assess the methodology of randomized controlled

trials of pharmacological and nonpharmacological interventions. *Phys Ther.* 2006;86(6):817-824.

455 31. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating
456 quality of randomized controlled trials. *Phys Ther.* 2003;83(8):713-721.

457 32. Murray E, Power E, Togher L, McCabe P, Munro N, Smith K. The reliability of methodological ratings
458 for speechBITE using the PEDro-P scale. *Int J Lang Commun Disord*. 2013;48(3):297-306.

33. Moseley AM, Herbert RD, Sherrington C, Maher CG. Evidence for physiotherapy practice: A survey of
the physiotherapy evidence database (PEDro). *Aust J Physiother*. 2002;48(1):43-9.

461 34. Brooks P, Hochberg M, ILAR, OMERACT. Outcome measures and classification criteria for the

462 rheumatic diseases. A compilation of data from OMERACT (outcome measures for arthritis clinical trials),

463 ILAR (international league of associations for rheumatology), regional leagues and other groups.

464 *Rheumatology (Oxford)*. 2001;40(8):896-906.

35. Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core set of outcome measures for future
phase III clinical trials in knee, hip, and hand osteoarthritis. consensus development at OMERACT III. J *Rheumatol.* 1997;24(4):799-802.

- 468 36. Mulrow CD, Oxman A. How to conduct a cochrane systematic review . [San Antonio Cochrane
- 469 Collaboration, version 3.0.2] ed. Oxford, United Kingdom: The Cochrane Library, The Cochrane
- 470 Collaboration; 1997.
- 471 37. Mulrow CD, Oxman A. How to conduct a cochrane systematic review. San Antonio Cochrane
- 472 Collaboration, version 3.0.2 ed. Oxford: The Cochrane Library; 1997.
- 473 38. Cochrane website. http://www.cochrane.org. Updated n.d. Accessed June 7, 2015.
- 474 39. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of
- improvement in juvenile arthritis. *Arthritis Rheum*. 1997;40(7):1202-1209.
- 476 40. Ringold S, Wallace CA. Measuring clinical response and remission in juvenile idiopathic arthritis. Curr
- 477 *Opin Rheumatol.* 2007;19(5):471-476.
- 478 41. Wells G, Tugwell P, Brosseau L, et al. Philadelphia panel evidence-based clinical practice guidelines
- 479 on selected rehabilitation interventions: Overview and methodology. *Phys Ther.* 2001;81(10):1629-1640.
- 480 42. Coda A, Carline T, Santos D. Chapter 4: Methods randomized controlled study. In: Foot orthoses in
- 481 children with juvenile idiopathic arthritis (JIA). LAP LAMBERT Academic Publishing; 2015:173-243.
- 482 43. Powell M, Seid M, FAU Szer IS, Szer IS. Efficacy of custom foot orthotics in improving pain and
- 483 functional status in children with juvenile idiopathic arthritis: A randomized trial. *J Rheumatol.*
- 484 2005;32(5):943-50.
- 44. Coda A, FAU Fowlie PW, Fowlie PW, et al. Foot orthoses in children with juvenile idiopathic arthritis:
 A randomised controlled trial. *Arch Dis Child*. 2014;99(7):649-51.

487 45. Hendry GJ, Watt GF, FAU - Brandon M, et al. The effectiveness of a multidisciplinary foot care
488 program for children and adolescents with juvenile idiopathic arthritis: An exploratory trial. *J Rehabil Med.*489 2013;45(5):467-76.

490 46. Ireys HT, Sills EM, Kolodner KB, Walsh BB. A social support intervention for parents of children with
491 juvenile rheumatoid arthritis: results of a randomized trial. Journal of Pediatric Psychology. 1996;
492 21(5):633-641.

493

494 47. Baydogan N, Tarakci E, Kasapcopur O. Comparison the effect to the lower extremity functions of

495 strengthening exercises and proprioceptive-balance exercises in juvenile idiopathic arthritis. Annals of the

496 Rheumatic Disease. 2013;71.

497

498 48. Carrasco R, Lovell DJ, Giannini EH, et al. Biochemical markers of bone turnover associated with

499 calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-

500 controlled intervention trial. *Arthritis & Rheumatism.* 2008;58(12):3932-3940.

501

49. Epps H, Ginnelly L, Utley M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of
combined hydrotherapy programmes compared with physiotherapy land techniques in children with
juvenile idiopathic arthritis. *Health Technology Assessment* (Winchester, England). 2005;9(39):iii-iv, ix-x,
1-59.

506

507 50. Field T, Hernandez-Reif M, Seligman S, et al. Juvenile rheumatoid arthritis: benefits from massage 508 therapy. *Journal of Pediatric Psychology*. 1997;22(5):607-617.

509

510 51. Hillman LS, Cassidy JT, Chanetsa F, Hewett JE, Higgins BJ, Robertson JD. Percent true calcium

511 absorption, mineral metabolism, and bone mass in children with arthritis: effect of supplementation with

vitamin D3 and calcium. *Arthritis & Rheumatism.* 2008;58(10):3255-3263.

- 513 52. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the
- 514 efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. Journal
- 515 of Rheumatology. 1997;24(11):2230-2232.
- 516
- 517 53. Lelieveld OT, Armbrust W, Geertzen JH, et al. Promoting physical activity in children with juvenile
- 518 idiopathic arthritis through an internet-based program: results of a pilot randomized controlled trial.
- 519 Arthritis care & research. 2010;62(5):697-703.
- 520 54. Mendonca TM, Terreri MT, Silva CH, et al. Effects of Pilates exercises on health-related quality of life
- 521 in individuals with juvenile idiopathic arthritis. Archives of Physical Medicine & Rehabilitation.
- 522 2013;94(11):2093-2102.
- 523 55. Stinson JN, McGrath PJ, Hodnett ED, et al. An internet-based self-management program with
- 524 telephone support for adolescents with arthritis: A pilot randomized controlled trial. Journal of
- 525 *Rheumatology*. 2010;37(9):1944-1952.
- 526
- 527 56. Takken T, Van Der Net J, Kuis W, Helders PJ. Aquatic fitness training for children with juvenile 528 idiopathic arthritis. *Rheumatology*. 2003;42(11):1408-1414.
- 529
- 530 57. Tarakci E, Yeldan I, Baydogan SN, Olgar S, Kasapcopur O. Efficacy of a land-based home exercise
- 531 programme for patients with juvenile idiopathic arthritis: a randomized, controlled, single-blind study.
- 532 Journal of Rehabilitation Medicine. 2012;44(11):962-967.
- 533
- 534 58. Alpigiani MG, Ravera G, Buzzanca C, Devescovi R, Fiore P, lester A. [The use of n-3 fatty acids in 535 chronic juvenile arthritis]. *Pediatria Medica e Chirurgica*. 1996;18(4):387-390.

537	59. Vargova V, Vesely R, Sasinka M, Torok C. Can administration of omega-3 unsaturated fatty acids
538	reduce the consumption of non-steroid antirheumatics in children with juvenile chronic arthritis?. [Slovak].
539	Casopis Lekaru Ceskych. 1998;137(21):651-653.
540	
541	60. Stark LJ, Janicke DM, McGrath AM, Mackner LM, Hommel KA, Lovell D. Prevention of osteoporosis:
542	a randomized clinical trial to increase calcium intake in children with juvenile rheumatoid arthritis. Journal
543	of Pediatric Psychology. 2005;30(5):377-386.
544	
545	61. Eberhard BA, Sylvester KL, Ansell BM. A comparative study of orthoplast cock-up splints versus
546	ready-made Droitwich work splints in juvenile chronic arthritis. Disability & Rehabilitation. 1993;15(1):41-
547	43.
548	
549	62. Hommel KA, Chaney JM, Wagner JL, Jarvis JN. Learned helplessness in children and adolescents
550	with juvenile rheumatic disease. Journal of Psychosomatic Research. 2006;60(1):73-81.
551	63. Lavigne JV, Ross CK, Berry SL, Hayford JR, Pachman LM. Evaluation of a psychological treatment
552	package for treating pain in juvenile rheumatoid arthritis. Arthritis Care & Research. 1992;5(2):101-110.
553	64. Jeppesen J, Christensen A, Herlin T, Leegaard A, Thastum M. Results of a waitlist controlled
554	psychological group treatment program for children with juvenile idiopathic arthritis and their parents.
555	Journal of Psychosomatic Research. 2012;72 (6):487.
556	65. Jeppesen JH, Herlin T, Christensen AE, Leegaard A, Thastum M. A waitlist controlled trial of the
557	efficacy of a psychological treatment program for children with juvenile idiopathic arthritis and their

558 parents. Annals of the Rheumatic Disease. 2013;71.

66. Sandstedt E. PReS-FINAL-2049: Bone health, muscle strength, activity. *Pediatric Rheumatology*.
2013;11.

561	67. Stern SM, Blitz JR, Richards A, Marzan KAB. A family based pedometer walking program in an
562	adolescent population with juvenile idiopathic arthritis. Arthritis and Rheumatism. 2012;64:S375-S376.
563	
564	68. Coda A, Davidson J, Walsh J, Fowlie P, Carline T, Santos D. Pre-formed orthoses in juvenile
565 566	idiopathic arthritis: Results from an RCT. <i>Rheumatology</i> (United Kingdom). 2012;51:iii107.
567	69. Hendry GJ, Watt GF, Brandon M, et al. Clinical and cost effectiveness of a multidisciplinary foot care
568	programme for children and adolescents with juvenile idiopathic arthritis: An exploratory trial.
569	Rheumatology (United Kingdom). 2013;52:i36.
570	
571	70. Sandstedt E, Fasth A, Fors H, Beckung E. Bone health in children and adolescents with juvenile
572	idiopathic arthritis and the influence of short-term physical exercise. Pediatric Physical Therapy.
573	2012;24(2):155-161; discussion 162.
574	
575	71. Lovell DJ, Glass D, Ranz J, et al. A randomized controlled trial of calcium supplementation to increase
576	bone mineral density in children with juvenile rheumatoid arthritis. Arthritis & Rheumatism.
577	2006;54(7):2235-2242.
578	
579	72. Stinson JN, McGrath PJ, Hodnett EE, et al. Feasibility testing of an online self-management program
580	for adolescents with juvenile idiopathic arthritis (JIA): A pilot randomized controlled trial. Arthritis and
581	Rheumatism. 2009;60:238.
582	
583	73. Tarakci E, Yeldan I, Baydogan S, Olgar S, Kasapcopur O. The efficacy of land-based home exercise
584	program in patients with juvenile idiopathic arthritis: A randomized-controlled, single-blind study. Annals of
585	the Rheumatic Disease. 2013;71.

- 587 74. Hendry G, Watt G, Brandon M, et al. A feasibility trial of multidisciplinary foot care for children and
 588 adolescents with juvenile idiopathic arthritis. *Internal Medicine Journal.* 2012;42:7.
- 589 75. Sowers MF, Yosef M, Jamadar D, Jacobson J, Karvonen-Gutierrez C, Jaffe M. BMI vs. body
- 590 composition and radiographically defined osteoarthritis of the knee in women: A 4-year follow-up study.
- 591 Osteoarthritis Cartilage. 2008;16(3):367-372.
- 592 76. AGREE: Advancing the science of practice guidelines. <u>http://www.agreetrust.org/</u>. Updated n.d.
 593 Accessed July 27, 2015.
- 594 77. Brosseau L, Rahman P, Toupin-April K, et al. A systematic critical appraisal for non-pharmacological
 595 management of osteoarthritis using the appraisal of guidelines research and evaluation II instrument.
 596 *PLoS One.* 2014;9(1):e82986.
- 597 78. American College of Rhematology. <u>http://www.rheumatology.org/</u>. Updated n.d. Accessed July 27,
 598 2015.
- 79. The European League Against Rheumatism. <u>http://www.eular.org/</u>. Updated n.d. Accessed July 27,
 2015.
- 601 80. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: An evidence based

approach to the management of knee osteoarthritis: Report of a task force of the standing committee for
international clinical studies including therapeutic trials (ESCISIT). *Ann Rheum Dis.* 2003;62(12):11451155.

81. Hochberg MC, Altman RD, April KT, et al. American college of rheumatology 2012 recommendations
for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)*. 2012;64(4):465-474.

- 608 82. Jane MacKenzie A, Rome K, Evans AM. The efficacy of nonsurgical interventions for pediatric flexible
- 609 flat foot: A critical review. J Pediatr Orthop. 2012;32(8):830-834.
- 610 83. Otter SJ, Lucas K, Springett K, et al. Foot pain in rheumatoid arthritis prevalence, risk factors and
- 611 management: An epidemiological study. *Clin Rheumatol.* 2010;29(3):255-271.
- 612 84. Nurse MA, Hulliger M, Wakeling JM, Nigg BM, Stefanyshyn DJ. Changing the texture of footwear can
- alter gait patterns. *J Electromyogr Kinesiol*. 2005;15(5):496-506.
- 85. Thorp L, Wimmer M, Sumner D, et al. Custom shoe inserts induce beneficial long-term gait
- adaptations in medial knee osteoarthritis. Arthritis Rheum. 2007;56:S120.
- 616 86. Nigg BM. The role of impact forces and foot pronation: A new paradigm. *Clin J Sport Med.*
- 617 2001;11(1):2-9.
- 618 87. Nigg BM, Nurse MA, Stefanyshyn DJ. Shoe inserts and orthotics for sport and physical activities. *Med*
- 619 Sci Sports Exerc. 1999;31(7 Suppl):S421-8.
- 620 88. Swinnen E, Kerckhofs E. Compliance of patients wearing an orthotic device or orthopedic shoes: A
- 621 systematic review. Journal of Bodywork and Movement Therapies. 2015;ePUB.
- 622 89. Straus SE, Tetroe J, Graham ID. *Knowledge translation in health care: Moving from evidence to*
- 623 *practice.* . 2nd edition ed. Chichester, West Sussex: Wiley BMJ/Books; 2013.
- 90. Dhanani S, Quenneville J, Perron M, Abdolell M, Feldman BM. Minimal difference in pain associated
- 625 with change in quality of life in children with rheumatic disease. *Arthritis Care & Research*.
- 626 2002;47(5):501-505.
- 91. SooHoo NF, Samimi DB, Vyas RM, Botzler T. Evaluation of the validity of the foot function index in
- measuring outcomes in patients with foot and ankle disorders. *Foot Ankle Int.* 2006;27(1):38-42.

- 629 92. Rapoff MA. Pediatric measures of pain: The pain behavior observation method, pain coping
- 630 questionnaire (PCQ), and pediatric pain questionnaire (PPQ). *Arthritis Care & Research*.
- 631 2003;49(S5):S90-S95.

1 Appendix 1. Study flow diagram (PRISMA)



5 Appendix 2. Characteristics of Included Studies

6

Author/ Year	Sample size	Population Details	Symptom duration or date of diagnosis	Age (Mean, SD for control)	Treatment	Comparison group	Concurrent therapy	Session/ week No. of weeks	Follow-up months	PEDro Score
Coda et al. 2014	60 recruited Gr 1: 31 Gr 2: 29	Inclusion criteria: diagnosed with JIA according to International League of Associations for Rheumatology criteria, disease onset from 5-18yr in lower extremity joint, previous failure in orthotic management (patient must not have worn any FO's for a period of 3 months minimum, able to walk at least 15 m without assistive devices, minimum of 6 months after start of disease modifying antirheumatic drug therapy Exclusion criteria: Linable to walk		Gr 1: 10.64 (3.84) Gr 2: 11.17 (3.51)	Gr 1: Slimflex- Plus FOs were used for the 'fitted FOs'. Participants were instructed to use the FOs gradually for the first few days and then to use them at all times.	Gr 2: The control FOs was made with leather board and did not have corrections. Participants were instructed to use the FOs gradually for the first few days and then to use them at all times.		Use: All the time for 6 months	End of treatment: 3 and 6 months	7

Author/ Year	Sample size	Population Details	Symptom duration or date of diagnosis	Age (Mean, SD for control)	Treatment	Comparison group	Concurrent therapy	Session/ week No. of weeks	Follow-up months	PEDro Score
		barefoot or shod, associated musculoskeletal disease, central or peripheral nerve disease and endocrine disorders, previous foot surgery, current FOs use, where supply of FOs is contraindicated				S	5			
Powell et al. 2005	48 screened; 40 completed Gr 1: 15/40 completed Gr 2: 12/40 completed Gr 3: 13/40 completed	Inclusion criteria: diagnosed with JIA, a minimum of 5 years of age, active disease determined by tender and swollen foot joint count of the ankle, subtalar, hindfoot, and/or metatarsal joints, at least 1 month but less than 2 years persistent foot/ankle pain, stable medication the month before entry and during		Gr 1: 12.14 (3.32) Gr 2: 12.17 (3.04) Gr 3: 13.77 (4.55)	Gr 1: Custom- made orthotics made of metal particle- reinforced polyolefin with shock absorbing functional post.	Gr 2: Prefabricated off-the-shelf shoes inserts made of 1/8" flat neoprene. Gr 3: New supportive athletic shoes with a medial longitudinal arch support and shock absorbing soles worn alone.		Use: All the time for 3 months	End of treatment: 3 months	7

Author/ Year	Sample size	Population Details	Symptom duration or date of diagnosis	Age (Mean, SD for control)	Treatment	Comparison group	Concurrent therapy	Session/ week No. of weeks	Follow-up months	PEDro Score
		the study and ability to walk at least 50 feet without assistance. Exclusion criteria: foot osseous anomaly, previous foot/ankle surgery, joint injections during and 6 months before study, and previous use of shoe inserts or foot orthotics.			,0,	Sex	5			
Hendry et al. 2013	Total: 44 Gr 1: 21 Gr 2: 23	Inclusion criteria: diagnosis of JIA according to International League of Associations for Rheumatology (ILAR), being treated at the Royal Hospital for Sick Children, arthritis in at least one of the foot joints (small or large joints) or	Disease duration, years, mean (SD) Gr 1: 3.74 (2.65) Gr 2: 4.06 (3.33)	Gr 1: 10.1 (4.22) Gr 2: 10.0 (3.39)	Gr 1: Consultations with a paediatric rheumatologist, podiatrist (orthotic therapy), physiotherapist and sonographer. Participants were advised on basic foot care, footwear,	Gr 2: out of the 23 participants, 5 had a referral to the standard care arm podiatrist (3 of them received FOS), 7 received ICIs, and participants received	The children received standard medical care during the study.	N/A	End of treatment at 6 and 12 months	6

Author/ Year	Sample size	Population Details	Symptom duration or date of diagnosis	Age (Mean, SD for control)	Treatment	Comparison group	Concurrent therapy	Session/ week No. of weeks	Follow-up months	PEDro Score
		polyarthritis of both the large and small joints in the foot. Children and adolescents receiving podiatric care. Exclusion criteria: unconfirmed JIA and arthritis in the upper limb, jaw or neck.		X	exercises and simple joint protection. Out of the 21 participants, 17 were prescribed FOs, 4 received Splints, 13 received MSUS-guided ICIs in the joint and/or around the soft tissue of the foot and ankle and participants received stable, new or higher dosed medications.	stable, new or higher dosed medications.	S			
		PC								

10 11	Appendix 3. Summary of Recommendations
12	Fitted FOs vs Control FOs (leather board (1mm) without corrections), level I RCT (N = 60, high quality [PEDro score 7/10]) (Coda 2014) ⁴⁴ :
13 14	 Grade C+ (clinically important benefit demonstrated without statistical significance) for: pain (VAS) at end of treatment 6 months.
15 16 17 18 19	 Grade C (no benefit demonstrated) for: pain (VAS), quality of life (PedsQL – pediatric rheumatology), quality of life (PedsQL – parent rheumatology), quality of life (PedsQL – child generic), quality of life (PedsQL – parent generic), quality of life (CHAQ), and gait velocity (cm/sec) at end of treatment 3 months; for quality of life (PedsQL – pediatric rheumatology), quality of life (PedsQL – parent rheumatology), quality of life (PedsQL – child generic), quality of life (PedsQL – pediatric rheumatology), quality of life (PedsQL – parent rheumatology), quality of life (PedsQL – child generic), quality of life (PedsQL – pediatric rheumatology), quality of life (PedsQL – parent rheumatology), quality of life (PedsQL – child generic), quality of life (PedsQL - parent generic), quality of life (CHAQ), gait time [s], and gait velocity [cm/sec] at end of treatment 6 months.
20	- Grade D (no benefit demonstrated but favouring control) for: gait time [s] at end of treatment 3 months.
21	Foot orthotics vs Shoe inserts, level 1 RCT (N = 27, high quality [PEDro score 7/10]) (Powell 2005) ⁴³ :
22 23 24 25	 Grade C+ (clinically important benefit demonstrated without statistical significance) for: pain intensity [Pediatric Pain Questionnaire (PPQ) – VAS], activity limitation [Foot Function Index (FFI)], foot pain (FFI), and disability (FFI) at end of treatment 3 months.
26 27	- Grade C (no benefit demonstrated) for: timed walking [s], physical functioning (PedsQL 4.0 Generic Core Scales, child self-report), and physical functioning (PedsQL 4.0 Generic Core Scales, parent proxy-report) at end of treatment 3 months.
28	Foot orthotics vs Shoes only, level I RCT (N = 28, high quality [PEDro score 7/10]) (Powell 2005) ⁴³ :
29 30 31	- Grade A (clinically important benefit demonstrated with statistical significance) for: pain intensity [Pediatric Pain Questionnaire (PPQ) - VAS], activity limitation [Foot Function Index (FFI)], foot pain (FFI), and disability (FFI) at end of treatment 3 months.
32 33	- Grade C (no benefit demonstrated) for: timed walking [s], physical functioning (PedsQL 4.0 Generic Core Scales, child self- report) and physical functioning (PedsQL 4.0 Generic Core Scales, parent proxy-report) at end of treatment 3 months.
34	Shoe inserts vs Shoes only, level I RCT (N = 25, high quality [PEDro score 7/10]) (Powell 2005):
35 36	 Grade C+ (clinically important benefit demonstrated without statistical significance) for: pain intensity [Pediatric Pain Questionnaire (PPQ) – VAS] at end of treatment 3 months.

37 38 Grade C (no benefit demonstrated) for: timed walking [s], activity limitation [Foot Function Index (FFI), foot pain (FFI), disability -39 (FFI), physical functioning (PedsQL 4.0 Generic Core Scales, child self-report), and physical functioning (PedsQL 4.0 Generic Core 40 Scales, parent proxy-report) at end of treatment 3 months. Multidisciplinary foot care vs Standard care, level I RCT (N = 44, high quality [PEDro score 6/10]) (Hendry 2013): 41 Grade C (no benefit demonstrated) for: activity limitation [Juvenile Arthritis Foot Disability Index (JAFIal)] at end of treatment 6 42 months; for: activity limitation (JAFIal), participation restriction (JAFIpr), pain (VAS), and health related quality of life (EQ-5D VAS 43 self) at end of treatment 12 months. 44 45 Grade D (no benefit demonstrated but favouring control) for: impairment (JAFlimp), and participation restriction (JAFlpr) at end 46 of treatment 6 months; for: impairment (JAFlimp), global functional status (CHAQ), and health related quality of life (EQ-5D VAS 47 proxy) at end of treatment 12 months. 48

R.C.C.

Study	Study Groups: Intervention (I) and Control (C)	Outcome	No. of Patients	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference in Change From Baseline	Mean Difference (MD) 95% Confidence Interval (CI)	Grade
Coda et al., 2014	I: Fitted FOs	Pain (VAS) Primary Outcome	31	22.51	16.45	-4.41	-20%	MD: -2.88 CI Low: -15.7	С
	C: Control FOs		29	20.98	19.33	\mathbf{O}		Cl High: 9.94	
Coda et al., 2014	I: Fitted FOs	Quality of life (PedsQL - paediatric rheumatology) Secondary Outcome	31	68.28	80.58	13.26	18%	MD: 5.92 CI Low: -3.58 CI High: 15.42	С
	C: Control FOs		29	75.62	74.66				
Coda et al., 2014	I: Fitted FOs	Quality of life (PedsQL - parent rheumatology) Secondary Outcome	31	67.29	76.37	4.49	6%	MD: 0.6 CI Low: -9.66 CI High: 10.86	С

49 Appendix 4. Fitted Foot Orthoses (FO) vs Control Foot Orthoses (FO) (End of Treatment: 3 months)

Study	Study Groups: Intervention (I) and Control (C)	Outcome	No. of Patients	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference in Change From Baseline	Mean Difference (MD) 95% Confidence Interval (CI)	Grade
	C: Control FOs		29	71.18	75.77				
Coda et al., 2014	I: Fitted FOs	Quality of life (PedsQL – child generic) Secondary Outcome	31	72.31	81.69	9.13	12%	MD: 2.9 CI Low: -6 CI High: 11.8	С
	C: Control FOs		29	78.54	78.79				
Coda et al., 2014	I: Fitted FOs	Quality of life (PedsQL – parent generic) Secondary Outcome	31	68.81	78.11	1.59	2%	MD:-0.8 CI Low: -10.58 CI High: 8.98	С
	C: Control FOs		29	71.2	78.91				
Coda et al., 2014	I: Fitted FOs	Quality of life (CHAQ) Secondary Outcome	31	0.6	0.46	0.11	17%	MD: 0.02 CI Low: -0.29 CI High: 0.33	С
	C: Control FOs		29	0.69	0.44				
Coda et al., 2014	I: Fitted FOs	Gait time (sec) Secondary Outcome	31	1.26	1.32	0.05	4%	MD: 0.12 CI Low: -0.12 CI High: 0.36	D

Study	Study Groups: Intervention (I) and Control (C)	Outcome	No. of Patients	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference in Change From Baseline	Mean Difference (MD) 95% Confidence Interval (CI)	Grade
	C: Control FOs		29	1.19	1.2				
Coda et al., 2014	I: Fitted FOs	Gait velocity (cm/sec) Secondary Outcome	31	109.7	108.63	1.27	1%	MD: -4.27 CI Low: -13.72 CI High: 5.18	С
	C: Control FOs		29	115.24	112.9				

N.C.C.

~

Appendix 5. Outcome Measure Characteristics*

Conflicting Outcome Measures: Same measured outcome with different recommendations						
Study	Outcome Measure	Characteristics				
Powell et al., 2005 ⁴³	Foot pain	 Instrument: Foot Function Index (FFI) Measured by: Self-administered Reliability and Validity: SooHoo, Samimi, Vyas, Botzler, et al., 2006^{43,63}† 				
	Pain intensity	 Instrument: Pediatric Pain Questionnaire–Visual Analog Scale (VAS: 0-10) Measured by: Self-administered Validity: Rapoff, 2003⁶⁴ 				

* Additional information within Discussion section of manuscript

† Not specifically validated for children

D	etails of the study	1	Improved Outcome Measures
Study	Population	Intervention Details	Grade possibilities: [A, B, C+, C, D, D+, D-]
Powell et al., 2005	 Dragnosed with JIA At least 5 years of age Active disease in the foot and ankle 	 Custom made shock absorbing orthotics with metal particle-reinforced polyolefin Shoe inserts Off-the-shelf shoes inserts pre- fabricated from flat neoprene Shoes only Supportive athletic shoes with arch support and shock absorbing soles 	 END OF TREATMENT (3 months): Foot orthotics vs Shoe inserts [C+] Pain intensity (PPQ: VAS) [C+] Activity limitation (FFI) [C+] Foot pain (FFI) [C+] Disability (FFI) Foot orthotics vs Shoes only [A] Pain intensity (PPQ: VAS) [A] Foot pain (FFI) [A] Foot pain (FFI) [A] Disability (FFI) Foot orthotics vs Shoes only [A] Disability (FFI) Foot orthotics vs Shoes only [A] Disability (FFI)
Coda et al., 2014 ⁴⁴	 Onset of disease between the ages of 5-18 Diagnosis of any JIA subtype Disease involvement in the joints of the lower limbs 	 Fitted Foot Orthoses Custom fitted preformed foot orthoses Patients gradually wore foot orthoses all the time after having tried them on 	END OF TREATMENT (6 months): - [C+] Pain (VAS)

Appendix 6. Positive EBCPG Recommendations with Study Details

Hendry et al., 2013 ⁴⁵	Children or adolescents with JIA	Multidisciplinary foot care	No positive recommendations
	Documented arthritis in the foot	Education on foot care, footwear, exercises and joint protection	
		 Possibility of foot orthoses, splints and/or ICIs 	
		 Stable, new, or higher dosed medication 	

ICI: Intra-articular corticosteroid injections; PPQ: Pediatric Pain Questionnaire: FFI: Foot Function Index; VAS : Visual Analogue Scale

Study	Primary Outcome		Secondary Outcome	
Coda et al., 201444	End of Treatment (3 months) End of Treatment (3 months)			
		Fitted	FOs vs Control FOs	
	Pain (VAS)	С	• Quality of life (PedsQL – paediatric	С
			rheumatology)	
			 Quality of life (PedsQL – parent 	C
			rneumatology)	C
			 Quality of life (PedsQL – child generic) 	C
			 Quality of life (PedsQL – parent 	С
			generic)	
			Quality of life (CHAQ)	С
			Gait velocity [cm/sec]	С
			Gait time [s]	D
	End of treatment (6 mo	nths)	End of treatment (6 months)	
		Fitted	FOs vs Control FOs	
	Pain (VAS)	C+	Quality of life (PedsQL – paediatric	С
			rneumatology)	C
			• Quality of life (PedsQL – parent rheumatology)	U
			 Quality of life (PedsOL – child 	С
			generic)	Ũ
			Quality of life (PedsQL - parent	С
			generic)	
			Quality of life (CHAQ)	C
			Gait time [s]	C
			Gait velocity [cm/sec]	C
Powell et al., 200543	End of Treatment (3 mo	onths)	End of Treatment (3 months)	
	F	oot ortl	notics vs Shoe inserts	
	Activity limitation	C+	Pain intensity [Pediatric Pain Output intensity [Pediatric Pain	C+
	(FFI) Foot pain (FFI)	C+	Questionnaire (PPQ) - VAS	C
	 Pool pairi (FFI) Disability (FFI) 	C+	Physical Eulerioning (PedsOL 4.0	C
		01	Generic Core Scales, child self-	Ŭ
			report)	
			• Physical Functioning (PedsQL 4.0	С
			Generic Core Scales, parent	
			proxy-report)	
	I	Foot ort	hotics vs Shoes only	
	Activity limitation	A	Pain intensity [(PPQ) - VAS]	A
	(FFI)		Timed walking [s]	С
		_	Physical functioning (PedsQL 4.0	С
	 Foot pain (FFI) 	A	Generic Core Scales, child self-	

Appendix 7. Comparison of Primary & Secondary Outcome Measures with Recommendations

	Disability (FFI)	A	 report) Physical Functioning (PedsQL 4.0 Generic Core Scales, parent proxy-report) 	С	
		Shoe ir	nserts vs Shoes only		
	 Activity limitation (FFI) Foot pain (FFI) Disability (FFI) 	C C C	 Pain intensity [(PPQ) - VAS] Physical functioning (PedsQL 4.0 Generic Core Scales, child self- report) Physical Functioning (PedsQL 4.0 Generic Core Scales, parent proxy-report) 	C+ C C	
Hendry et al., 201345	End of Treatment (6 mo	onths)	End of Treatment (6 months)		
	 Activity limitation (JAFIal) Impairment (JAFIimp) Participation 	C D D	No secondary outcomes were measu	red	
	restriction (JAFIpr)				
	End of Treatment (12 months)		End of Treatment (12 months)		
	 Activity limitation (JAFIal) Impairment (JAFlimp) 	C D	 Pain (VAS) Health related quality of life (EQ- 5D VAS self) 	C C	
	Participation restriction (JAFIpr)	D			

* Conflicting recommendations between instruments measuring similar outcomes are explained within the discussion

† Long term effects were noted for these outcome measures

FFI: Foot Function Index; VAS: Visual Analogue Scale; JAFI: Juvenile Arthritis Foot Disability Index; PedsQL: Pediatric Quality of Life Inventory; PPQ: Pediatric Pain Questionnaire; CHAQ: Childhood Health and Assessment Questionnaire